drugset / Trial / NCT05942963

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

NCT05942963

Phase 4 Unknown 240 enrolled Jinnah Postgraduate Medical Centre
RandomizedFactorialSingle-blindTreatment

Summary

This clinical trial will yield results about the therapeutic effect of combining pioglitazone with SGLT2i in people suffering from NAFLD associated with T2DM. Study participants will be asked to fill out a few questions on proforma that will obtain demographic information as well as information relating to their health. In addition, some blood tests will be done following standard procedures.

Timeline

Start
2023-10
Primary completion
2024-04
Completion
2024-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg
Subject Pioglitazone Small molecule 15 mg
Background Metformin Small molecule